How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,654 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Serum Hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative Chronic Hepatitis B. (Abstract)

Serum Hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative Chronic Hepatitis B. The discrimination between active chronic hepatitis B (CHB) and the clinically quiescent infection (CIB) is not always easy, as a significant portion of patients falls in a "grey" zone. Hepatitis B core-related antigen (HBcrAg) is a now quantifiable serological marker with potential applications in diagnosis and therapy monitoring. The aim of the present study (...) -negative patients, HBcrAg results weakly correlated with qHBsAg levels (Spearman r = 0.471, P < 0.0001) and correlated closely with HBV-DNA (Spearman r = 0.746, P < 0.0001). HBcrAg levels were significantly higher in 85 CHB patients relative to 75 CIB carriers. A value of 2.5 logU/mL produced the optimal cut-off to identify CIB patients, with diagnostic accuracy comparable to HBsAg levels. In long-term clinical evaluation, a single measurement of HBcrAg at the established cut-off was optimally

2018 Journal of viral hepatitis

22. The association between PIN1 genetic polymorphisms and the risk of chronic hepatitis B and hepatitis B virus-related liver cirrhosis: A case-control study. Full Text available with Trip Pro

The association between PIN1 genetic polymorphisms and the risk of chronic hepatitis B and hepatitis B virus-related liver cirrhosis: A case-control study. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) reportedly plays a crucial role in tissue inflammation and tumourigenesis. Our previous studies have demonstrated that PIN1 gene polymorphisms are significantly related to the pathogenesis of hepatitis B virus (HBV)-related liver cancer in a Guangxi population. As chronic (...) hepatitis B (CHB), liver cirrhosis (LC), and liver cancer are development processes, we further investigated whether any relationship exists between PIN1 gene polymorphisms and the risk of CHB and HBV-related LC. We used the polymerase chain reaction restriction fragment length polymorphism and the deoxyribonucleic acid sequencing method to analyze 3 common single-nucleotide polymorphisms (SNPs) (rs2233678, rs2233679, and rs2233682) of the PIN1 gene in 192 CHB patients, 171 HBV-related LC patients

2018 Medicine

23. Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg) Full Text available with Trip Pro

Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg) BACKGROUND The aim of this study was to investigate the clinical characteristics of individuals with chronic hepatitis B virus (HBV) infection with persistent low levels of hepatitis B surface antigen (HBsAg) and to undertake a correlation analysis of the clinical characteristics. MATERIAL AND METHODS The study included (...) 1,204 subjects with chronic HBV infection. Serum HBsAg, HBV envelope antigen (HBeAg), and HBV core antigen (HBcAg) levels were measured using the chemiluminescent microparticle immunoassay (CMIA) and the neutralization test. HBV DNA was measured using real-time fluorescence quantitative polymerase chain reaction (RT-FQ-PCR). RESULTS There were 1,023 subjects in the high-level HBsAg group (HBsAg level ≥10 IU/mL) and 181 subjects in the low-level HBsAg group (HBsAg level <10 IU/mL). In the low-level

2018 Medical science monitor : international medical journal of experimental and clinical research

24. Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

Hepatitis B Biological: hepatitis B immune Drug: Pegylated interferon alfa Phase 2 Detailed Description: Up to 300 subjects with hepatitis B e antigen (HBeAg) negative chronic hepatitis B who are inactive carriers (specified as those with HBV DNA levels <2,000 IU/ml over a 6-month period with ALT levels <1.5 X upper limit of normal and HBsAg level <1500 U/mL) will be screened and 25 enrolled in a randomized trial of hepatitis B immune globulin (HBIg) for 12 weeks followed by peginterferon alfa for 24 (...) Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

25. Hepatitis B (chronic) : diagnosis and management

to as the 'inactive HBV carrier state' when HBeAg has been cleared, anti-HBe is present and HBV DNA is undetectable or less than 2000 IU/ml. Once seroconversion has taken place, most people remain in the inactive HBV carrier state (the immune-control phase; see figure 1). However, increasing HBV DNA and recurrent hepatitis after seroconversion indicate the emergence of the HBeAg-negative strain of the virus (the immune-escape phase; see figure 1). Hepatitis B (chronic): diagnosis and management (CG165) © NICE (...) Hepatitis B (chronic) : diagnosis and management Hepatitis B ( Hepatitis B (chronic): diagnosis and chronic): diagnosis and management management Clinical guideline Published: 26 June 2013 nice.org.uk/guidance/cg165 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

26. The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children. Full Text available with Trip Pro

The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children. Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in children after universal hepatitis B immunization. This study aimed to investigate the natural course of chronic HBV infection in children with vaccine failure and compare it with that of nonvaccinated children.Three hundred fifty-six hepatitis B e antigen (...) (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, who were followed for at least 1 year without antiviral therapy, were enrolled. These comprised 105 vaccine failure subjects who received 3 doses of HBV vaccine in infancy and 251 nonvaccinated subjects. The clinical, serologic, and virologic features were compared between the 2 groups.The cumulative HBeAg seroconversion rate was significantly lower in the vaccine failure group than in the nonvaccinated group (30.5% vs 77.7

2017 Journal of Infectious Diseases

27. Epidemiology of Chronic Hepatitis B in Turkey Full Text available with Trip Pro

Epidemiology of Chronic Hepatitis B in Turkey Hepatitis B virus (HBV) infection is a global public health problem and it is also a major health concern of Turkey. The estimated number of HBV carriers in Turkey is about 3.3 million, with an overall HBV prevalence of 4.57%. Thus, both prevention and therapy of HBV-infected patients are urgent medical need of Turkey. A total of 1,533 among 37,637 patients who were examined at the Department of Gastroenterology, Ankara University School of Medicine (...) were found to be hepatitis B surface antigen (HBsAg) positive (4%). Viral hepatitis treatment is fully reimbursed in Turkey through the national insurance system, which covers all residents across Turkey. How to cite this article: Özkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepato-Gastroenterol 2018;8(1):73-74.

2018 Euroasian journal of hepato-gastroenterology

28. Chronic Hepatitis B Carrier

Chronic Hepatitis B Carrier Chronic Hepatitis B Carrier Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Chronic Hepatitis B Carrier (...) Chronic Hepatitis B Carrier Aka: Chronic Hepatitis B Carrier , Hepatitis B Carrier From Related Chapters II. Pathophysiology B Infection becomes chronic in 10% ( present >6 months) Chronic Hepatitis B Carrier Hepatitis B Carrier contrasted with chronic infection Low viral load Normal s (ALT or ) III. Labs positive negative positive s (ALT or ) normal Low viral load: HBV DNA hybridization negative IV. Management Observation: primary care visits every 6-12 months Follow related lab-work at follow-up

2018 FP Notebook

29. Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases. (Abstract)

Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases. Chronic hepatitis B virus (HBV) infection is associated with a lower incidence of colorectal liver metastases. We explored the impact of HBV carrier status on outcomes of surgical treatment of colorectal liver metastases.A retrospective analysis was conducted for consecutive patients undergoing liver resection for colorectal liver metastases from 2000 to 2016. HBV carriers were matched (...) with controls by propensity scoring.304 patients with known HBV carrier status who underwent resection of colorectal liver metastases were studied. From the 21 (6.9%) hepatitis B carriers, a more prolonged prothrombin time (12.1 vs. 11.3 s, OR 1.42, p = 0.027) was observed, and fewer major resections were performed (19.0 vs. 47.3%, OR 0.262, p = 0.018). After 1:5 propensity score matching, they were compared with 105 controls with similar liver function, tumour status and receiving similar treatments

2018 World Journal of Surgery

30. Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase. Full Text available with Trip Pro

Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase. The natural history of chronic hepatitis B virus (HBV) infection was divided into 4 phases. Patients in the inactive carrier (IC) status and immune tolerant (IT) phase had normal alanine aminotransferase levels but huge different viral loads. The mechanism underlying low viral replication status in IC phase is unknown.We determined the intrahepatic transcriptomes (...) of 83 chronic hepatitis B patients by microarray analysis of liver biopsies, and screened the effect of differentially regulated genes on HBV replication using specific small interfering RNAs in vitro.The gene profile distinguishing active chronic hepatitis from IT and IC was predominantly composed of immune-related genes. The liver transcriptomes between the IT and IC phase were largely similar, and 109 expressed genes were significantly different. By performing systematic screening, 5 candidate

2018 Journal of Infectious Diseases

31. Should Treatment Indications for Chronic Hepatitis B Be Expanded? (Abstract)

Should Treatment Indications for Chronic Hepatitis B Be Expanded? Antiviral therapy has greatly improved the outcomes of patients with chronic hepatitis B virus (HBV) infection and active liver disease or advanced fibrosis/cirrhosis. However, current treatment does not eradicate HBV and long-term treatment is needed in most patients to maintain clinical benefit. Thus, professional society guidelines do not recommend treatment of all patients with chronic HBV infection. This review article (...) will examine evidence for and against expansion of treatment to patients in whom treatment is not recommended based on current guidelines.Available data support expanding treatment to immune tolerant patients and patients in the grey zones who have evidence of active/advanced liver disease based on liver biopsy or non-invasive tests and those who remain in the immune tolerant phase after age 40. Evidence supporting treatment expansion to confirmed inactive carriers and other immune tolerant patients

2020 Clinical Gastroenterology and Hepatology

32. Chronic Hepatitis B Infection in Children and Its Relation to Pulmonary Function Tests: A Case-control Study. (Abstract)

Chronic Hepatitis B Infection in Children and Its Relation to Pulmonary Function Tests: A Case-control Study. The aim of this study was to evaluate the pulmonary function test (PFT) abnormalities, if any, in children with newly diagnosed chronic hepatitis B (CHB) infection over 3 years.This is an observational case-control study. One hundred children and adolescents with newly diagnosed CHB were enrolled as the patient group that was further subdivided into 2 groups (50 patients each): inactive (...) carriers (group I) and patients in immunotolerant phase (group II). Only 90 patients completed the study. Fifty healthy children of matched age, sex and height served as a control group, only 45 of them completed the study. PFTs in the form of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, residual volume, total lung capacity, mid-forced expiratory flow of 25%-75% and diffusing capacity of the lung for carbon monoxide were evaluated in all studied children at the start

2020 Pediatric Infectious Dsease Journal

33. Hepatitis B

interferon-alfa. Definition Hepatitis B virus (HBV) is a DNA virus transmitted by percutaneous and permucosal routes. HBV infection is also a sexually transmitted disease. Infection may result in a self-limiting disease requiring no treatment, particularly in adult-acquired infection, but it may also result in a chronically infected state, particularly if it is acquired perinatally or in early childhood. History and exam presence of risk factors normal physical examination jaundice hepatomegaly ascites (...) of Medicine Division of Liver Diseases Mount Sinai Hospital New York NY Disclosures JA declares that he has no competing interests. Dr Jawad Ahmad would like to gratefully acknowledge Dr Sateesh R. Prakash, Dr Siddarth Verma, Dr Smruti R. Mohanty, and Dr Jared Hossack, previous contributors to this monograph. SRP, SV, and JH declare that they have no competing interests. SRM serves as a speaker bureau for Bristol-Myers Squibb regarding the use of entecavir for the treatment of chronic hepatitis B. Peer

2018 BMJ Best Practice

34. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. (Abstract)

DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. The remission rates after stopping antivirals in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) vary among studies, while reliable predictors of relapse have not been identified. This prospective study assessed rates and predictors of relapse and retreatment in 57 non-cirrhotic hepatitis B surface antigen (...) shows that effective ≥4-year entecavir/TDF therapy can be safely discontinued in non-cirrhotic HBeAg-negative CHB patients. The probability of relapse decreased after month 6. Despite common virological relapses, most patients, particularly those with mild-moderate pretreatment fibrosis, remain without retreatment, at least in the first 18 months, as a substantial proportion of them clear HBsAg and the majority eventually enters into an inactive carrier state.

2018 Antiviral Therapy

35. The Role of Promyelocytic Leukemia Protein in Steatosis-Associated Hepatic Tumors Related to Chronic Hepatitis B virus Infection Full Text available with Trip Pro

The Role of Promyelocytic Leukemia Protein in Steatosis-Associated Hepatic Tumors Related to Chronic Hepatitis B virus Infection The persistence of hepatitis B surface antigen (HBsAg) is a risk factor for the development of steatosis-associated tumors in chronic hepatitis B virus (HBV) infection, yet little is known about the metabolic link with this factor. We correlated HBV-related pathogenesis in genetically engineered mice and human carriers with metabolic proteomics and lipogenic gene (...) in concordance to the increased severity of lipodystrophy and neoplasia in the livers of HBsAg-transgenic mice with PML insufficiency. The defect in lipolysis in PML-deficient HBsAg-transgenic mice made the HBsAg-induced adipose-like liver tumors vulnerable to synthetic lethality from toxic saturated fat accumulation with a Scd1 inhibitor. Our findings provide mechanistic insights into the evolution of steatosis-associated hepatic tumors driven by reciprocal interactions of HBsAg and PML, and a potential

2018 Translational oncology

36. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis

al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. QJM 1991;78:155-163. 26. Gregorio GV, Jara P, Hierro L, Diaz C, de la Vega A, Vegnente A, et al. Lymphoblastoid interferon alfa with or without steroid pretreat- ment in children with chronic hepatitis B: a multicenter controlled trial. HEPATOLOGY 1996;23:700-707. 27. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. Clinical trial of lamivudine in children (...) Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis Antiviral Therapy in Management of Chronic Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis Maureen M. Jonas, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Robert S. Brown, Jr., 4 John B. Wong, 5 Ahmed T. Ahmed, 6,7 Wigdan Farah, 6,7 Mohamed A. Mouchli, 8 Siddharth Singh, 9 Larry J. Prokop, 10 Mohammad Hassan Murad, 6,7,11 and Khaled Mohammed 6,7,11

2016 American Association for the Study of Liver Diseases

37. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis

to 600,000 of the approximately 240 mil- lion carriers worldwide die annually due to chronic hep- atitis B (CHB)-related disease. 1 Perinatal or mother-to- child transmission (MTCT) is the most common form of transmission of HBV in many high-prevalence areas 2,3 and may occur in up to 90% of mothers who are hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen (HBeAg)-positive in the absence of Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine (...) . Gastroenterology 1987;92: 1839-1843. 6. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. HEPATOLOGY 1988;8:1130- 1133. 7. Liaw YF , Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-spe- ci?c prevalence and signi?cance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocel- lular carcinoma. J Med Virol 1984;13:385-391. 8

2016 American Association for the Study of Liver Diseases

38. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION MARCH 2015 GUIDELINESGUIDELINES GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION MARCH 2015WHO Library Cataloguing-in-Publication Data Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 1.Hepatitis B – prevention (...) ACKNOWLEDGEMENTS IX ABBREVIATIONS AND ACRONYMS XII GLOSSARY OF TERMS XV EXECUTIVE SUMMARY XIX Summary of recommendations for persons with chronic hepatitis B infection xxii Algorithm of WHO recommendations on the management of persons with chronic hepatitis B infection xxvi Structure of the guidelines along the continuum of care xxviii 1. INTRODUCTION 1 1.1. Goals and objectives 1 1.2. Related WHO materials and guidelines 2 1.3. Target audience 2 1.4. Guiding principles 2 2. METHODOLOGY AND PROCESS

2015 World Health Organisation Guidelines

39. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION MARCH 2015 GUIDELINESGUIDELINES GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION MARCH 2015WHO Library Cataloguing-in-Publication Data Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 1.Hepatitis B – prevention (...) ACKNOWLEDGEMENTS IX ABBREVIATIONS AND ACRONYMS XII GLOSSARY OF TERMS XV EXECUTIVE SUMMARY XIX Summary of recommendations for persons with chronic hepatitis B infection xxii Algorithm of WHO recommendations on the management of persons with chronic hepatitis B infection xxvi Structure of the guidelines along the continuum of care xxviii 1. INTRODUCTION 1 1.1. Goals and objectives 1 1.2. Related WHO materials and guidelines 2 1.3. Target audience 2 1.4. Guiding principles 2 2. METHODOLOGY AND PROCESS

2015 World Health Organisation HIV Guidelines

40. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. (Abstract)

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Among individuals with chronic hepatitis B, those with hepatitis B e-antigen (HBeAg)-negative chronic hepatitis (CHB) can be difficult to distinguish from those with HBeAg-negative chronic HBV infection, also referred to as inactive HBV carriers (ICs), but both require different medical management. The level of HBV surface antigen (HBsAg) has (...) of hepatitis B. Individuals in the IC phase had significantly lower proportions of LHBs and MHBs than patients in acute or chronic phases irrespective of their HBV e-antigen status (p<0.0001) or HBsAg level. Both LHBs and MHBs ratios better predicted the IC phase than total HBsAg levels.Quantification of MHBs, particularly LHBs represents a novel tool for the identification of the IC stage.© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights

2017 Gut

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>